All patients treated with TG4050 in the Phase I part of the trial remained disease-free after a minimum of two years of follow-up, confirming clinical proof of principle. Translational data showed ...

Here we investigated the use of VSV as an oncolytic agent ... then incubated for 16 h. Virus diluted in medium to an appropriate MOI was added to the dishes and allowed to adsorb for 30 min ...

sjtu.edu.cn Background Deregulation of Bcl2 pathway is implicated in the pathogenesis of uveal melanoma (UM). Oncolytic adenovirus H101 is the world's first oncolytic viral therapy for cancer approved ...